NCT06603506招募中不适用
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Centre Francois Baclesse1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2024年11月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Rate of establishment of exploitable tumor organoid lines
研究概览
简要总结
This study comprises 3 stages:
- Collection of tumor and blood samples.
- Creation of organoid models based on tumor samples.
- Development of functional tests to predict clinical response to treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patient aged 18 years or more
- •Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
- •Patient with localized endometrial cancer, presenting:
- •A high-grade endometrioid histological type and/or
- •P53 mutation and/or
- •a non-endometrioid histological type regardless of P53 status.
- •Patient affiliated to a social security scheme
- •Information and signature of informed consent prior to any specific study procedure
排除标准
- •Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
- •Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
结局指标
主要结局
Rate of establishment of exploitable tumor organoid lines
时间窗: through study completion, an average of 3 years
Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Construction of Gynecological Tumor OrganoidsGynecologic CancerOrganoidNCT06155370Peking Union Medical College Hospital200
招募中
不适用
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic DecisionsUndifferentiated CarcinomaNCT06612827Centre Francois Baclesse20
Unknown
不适用
Tissue Bank of Biological Specimens From Patients With Gynecologic DiseaseEndometrial NeoplasmsUterine Cervical NeoplasmsOvarian NeoplasmsLeiomyomaNCT00299481U.S. Army Medical Research and Development Command7,000
招募中
不适用
Individualized Precision Treatment Based on Ovarian Cancer Organoid ModelOvarian CancerNCT05813509The First Affiliated Hospital of Xiamen University30
已完成
不适用
Collecting Tumor Samples From Patients With Gynecological TumorsBorderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedChildhood Embryonal RhabdomyosarcomaChildhood Malignant Ovarian Germ Cell TumorEndometrioid Stromal SarcomaGestational Trophoblastic TumorMalignant MesotheliomaMalignant Ovarian Epithelial TumorNeoplasm of Uncertain Malignant PotentialOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Serous CystadenocarcinomaPaget Disease of the VulvaMelanomaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian CancerStage I Uterine Corpus CancerStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Cervical CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage II Uterine Corpus CancerStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Cervical CancerStage III Uterine Corpus CancerStage III Vaginal CancerStage III Vulvar CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerStage IV Uterine Corpus CancerStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerUterine Corpus CancerUterine Corpus LeiomyosarcomaVulvar Squamous Cell CarcinomaNCT00897442Gynecologic Oncology Group275